Praluzatamab-MMAE, an ADC, comprises an ALCAM-targeted antibody conjugated with Monomethyl auristatin E (MMAE), and is utilized in breast cancer research.
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted
